Alzheimer's Disease Cooperative Study

阿尔茨海默病合作研究

基本信息

批准号：
9528004
负责人：
Howard Feldman
金额：
$ 372.37万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-07-01 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9528004
关键词：
Adrenergic Agents Affect Age Aging Alzheimer&apos s Disease Alzheimer&apos s disease risk Amyloid Attention Behavior assessment Behavioral Symptoms Biostatistics Core Biotechnology Clinical Course of Disease Clinical Trials Clinical Trials Design Cognition Collaborations Controlled Clinical Trials Data Data Analyses Data Set Dementia Development Device or Instrument Development Disease Disease Progression Drug Industry Drug Kinetics Enrollment Epidemic Epidemiology Europe Exercise Family Funding Goals Grant Healthcare Home environment Individual Industry Intervention Intervention Studies Laboratory Study Link Methodology Methods Minority Enrollment Minority Groups Minority Recruitment Modeling Multicenter Trials Patient Outcomes Assessments Pharmacodynamics Pharmacologic Substance Pharmacological Treatment Phase Placebos Population Prazosin Prevention Privatization Process Publications Recruitment Activity Research Research Design Research Methodology Research Personnel Resources Risk Safety Sampling Studies Site Testing Therapeutic Therapeutic Trials Underrepresented Minority Work actigraphy base cognitive change computerized cooperative study data sharing design effective therapy experience improved innovation instrument mild cognitive impairment minority subjects neuroimaging non-demented novel outreach phase 2 study pre-clinical prevent programs symptom treatment therapy development trial design

项目摘要

The overall aim of the ADCS is to advance research in the development of interventions that might be useful for treating, delaying, or preventing AD, particularly interventions that might not be developed by industry. In particular, the ADCS "has focused on instrument and trial methodology, and the testing of potential therapeutics that might not otherwise be studied by the pharmaceutical industry. For the coming grant cycle, the ADCS will continue its efforts to advance therapeutics through controlled clinical trials, development o novel instruments and trial designs, recruitment efforts (with particular attention to recruitment f minority subjects). The organization will continue its recent emphasis on collaboration and data sharing. Specific Aims: Aim 1: Test interventions to Improve cognition, slow the rate of decline, or delay/prevent the onset of AD. Three of the four projects in this application aim to slow disease progression. Aim 2: Test an intervention to ameliorate behavioral symptoms. We will extend promising early results supporting an adrenergic approach amelioration of behavioral symptoms with a multicenter trial of prazosin. Aim 3: Design new instruments for use in clinical trials. For the present cycle, we have incorporated instrument development into our largest project, the A4 trial. Aim 4: Develop novel and innovative approaches to AD clinical trial design. The A4 trial utilizes a new trial design to test a leading intervention at the earliest feasible stge of disease, preclinical AD. Aim 5: Develop novel and innovative approaches to AD clinical trial analysis. The Biostatistics Core will continue efforts to advance analytical approaches to AD trial design. Work will continue on optimal modeling of longitudinal data, including novel methods to link diverse datasets. Aim 6:.Expand the range of individuals studied in AD studies to include at-risk individuals and those with MCI. The ADCS has focused its methodological research on early-stage trials, and for this cycle, the two largest projects target preclinical AD and mild cognitive impairment. Aim 7: Enhance the recruitment of minority groups into AD studies. For the coming cycle, the ADCS Minority Recruitment Core will expand outreach efforts, and we will require sites to meet minority enrollment targets in our two largest trials.

ADC的总体目的是提高研究干预措施的发展，这些干预措施可能对治疗，延迟或预防广告有用，尤其是行业可能无法开发的干预措施。特别是，ADC“专注于仪器和试验方法，以及药物行业可能无法研究的潜在治疗学的测试。在即将到来的赠款周期中，ADC将继续其努力通过对照临床试验，开发O新颖的工具和招聘工作（特别是招聘人员的招聘人员）来促进临床试验，开发o型和招聘人员的努力。目的：1：在此应用程序中的四个项目中的三个项目中，要改善认知的测试干预措施当前的周期，我们将仪器开发纳入了我们最大的项目A4试验中。 AIM 4：开发新颖和创新的方法来进行AD临床试验设计。 A4试验利用新的试验设计来测试最早可行的疾病临床前AD的主要干预措施。目标5：开发新颖和创新的方法来进行AD临床试验分析。生物统计学核心将继续努力推进AD试验设计的分析方法。纵向数据的最佳建模将继续进行，包括链接各种数据集的新方法。 AIM 6：。扩展在AD研究中研究的个体范围，包括处于危险中的个体和具有MCI的人。 ADC将其方法论研究重点放在早期试验上，在本周期中，两个最大的项目针对临床前AD和轻度认知障碍。目标7：将少数群体招募到AD研究中。在即将到来的周期中，ADCS少数民族招聘核心将扩大外展活动，我们将要求网站在我们的两项最大试验中实现少数族裔入学目标。